Standard BioTools Inc.
Financials
Valuation Metrics
Standard BioTools Inc.'s Market Cap is $301M. At end of 2025 it was $493M. Ranked #2956 of 3,121 in US market (top 95%), #1337 of 1,463 on NASDAQ (top 91%), #187 of 205 in Health Care Equipment & Services (top 91%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $301M | US#2,956/3,121 Sec#187/205 |
| Revenue | $85M | US#2,731/3,121 Sec#189/205 |
| Net Income | $-87M | US—/3,121 Sec—/205 |
| Total Assets | $627M | US#2,687/3,121 Sec#152/205 |
| Net Assets | $540M | US#2,181/3,121 Sec#109/205 |
| Employees | 387 | US#2,350/3,121 Sec#161/205 |
| Value | ||
| P/B | 0.56x | US#71/3,121 Sec#4/205 |
| P/S | 3.55x | US#1,868/3,121 Sec#130/205 |
| FCF Yield | -27.48% | US—/3,121 Sec—/205 |
| Profitability | ||
| ROE | -16.18% | US#2,445/3,121 Sec#145/205 |
| ROA | -13.93% | US#2,730/3,121 Sec#165/205 |
| Op. Margin | -94.80% | US#2,737/3,121 Sec#193/205 |
| Revenue Growth | -36.71% | US#2,731/3,121 Sec#198/205 |
| Financial Health | ||
| Debt Ratio | 16.16% | US#187/3,121 Sec#18/205 |
| Total Debt | $28M | US#2,706/3,121 Sec#164/205 |
| FCF | $-83M | US#2,600/3,121 Sec#186/205 |
| Cash | $270M | US#1,498/3,121 Sec#87/205 |
| Current Ratio | 9.10x | US#288/3,121 Sec#15/205 |
| Performance | ||
| 1Y Return | -45.40% | US#2,870/3,121 Sec#188/205 |
| 1M Return | 14.62% | US#234/3,121 Sec#33/205 |
| From 52W High | -55.24% | US#2,881/3,121 Sec#187/205 |
| 1Y MDD | -61.79% | US#2,819/3,121 Sec#176/205 |
| Trading | ||
| Volume | 1,843,764 shares | US#1,789/3,121 Sec#122/205 |
| Trading Value | $1M | US#3,075/3,121 Sec#202/205 |
| Per Share | ||
| EPS | $-0.22 | US—/3,121 Sec—/205 |
| BPS | $1.38 | US#2,646/3,121 Sec#175/205 |
Company Info
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses. The company also provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in November 2001. Standard BioTools Inc. was incorporated in 1999 and is headquartered in Boston, Massachusetts.